TD Asset Management Inc Purchases 235,176 Shares of Roivant Sciences Ltd. $ROIV

TD Asset Management Inc grew its position in shares of Roivant Sciences Ltd. (NASDAQ:ROIV) by 74.4% in the 4th quarter, HoldingsChannel reports. The firm owned 551,376 shares of the company’s stock after acquiring an additional 235,176 shares during the quarter. TD Asset Management Inc’s holdings in Roivant Sciences were worth $11,965,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in ROIV. Goldman Sachs Group Inc. lifted its stake in Roivant Sciences by 15.4% during the first quarter. Goldman Sachs Group Inc. now owns 2,433,386 shares of the company’s stock worth $24,553,000 after purchasing an additional 324,764 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in Roivant Sciences by 1.4% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,445,807 shares of the company’s stock worth $24,678,000 after purchasing an additional 34,341 shares during the last quarter. American Century Companies Inc. lifted its stake in Roivant Sciences by 1.9% during the second quarter. American Century Companies Inc. now owns 89,625 shares of the company’s stock worth $1,010,000 after purchasing an additional 1,689 shares during the last quarter. Russell Investments Group Ltd. lifted its stake in Roivant Sciences by 149.9% during the second quarter. Russell Investments Group Ltd. now owns 11,467 shares of the company’s stock worth $129,000 after purchasing an additional 6,879 shares during the last quarter. Finally, M&T Bank Corp lifted its stake in Roivant Sciences by 10.2% during the second quarter. M&T Bank Corp now owns 12,802 shares of the company’s stock worth $144,000 after purchasing an additional 1,181 shares during the last quarter. Institutional investors own 64.76% of the company’s stock.

Insider Transactions at Roivant Sciences

In other Roivant Sciences news, CEO Matthew Gline sold 289,774 shares of the company’s stock in a transaction that occurred on Thursday, April 16th. The stock was sold at an average price of $29.16, for a total transaction of $8,449,809.84. Following the transaction, the chief executive officer owned 16,736,116 shares in the company, valued at approximately $488,025,142.56. This represents a 1.70% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Melissa B. Epperly sold 41,861 shares of the company’s stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $28.68, for a total value of $1,200,573.48. Following the transaction, the director owned 15,804 shares in the company, valued at $453,258.72. This trade represents a 72.59% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 945,173 shares of company stock worth $27,654,456 over the last quarter. Insiders own 10.80% of the company’s stock.

Roivant Sciences Stock Performance

ROIV stock opened at $28.49 on Tuesday. Roivant Sciences Ltd. has a fifty-two week low of $10.70 and a fifty-two week high of $32.79. The business’s 50 day moving average price is $28.78 and its two-hundred day moving average price is $25.76. The company has a market capitalization of $20.49 billion, a price-to-earnings ratio of -47.48 and a beta of 1.13.

Roivant Sciences (NASDAQ:ROIV) last posted its earnings results on Wednesday, May 20th. The company reported $0.28 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.57. Roivant Sciences had a negative return on equity of 20.54% and a negative net margin of 3,629.19%.The firm had revenue of $2.52 million for the quarter, compared to the consensus estimate of $3.41 million. During the same quarter in the prior year, the business earned ($0.29) EPS. Sell-side analysts forecast that Roivant Sciences Ltd. will post -1.83 earnings per share for the current year.

Analysts Set New Price Targets

Several brokerages have issued reports on ROIV. HC Wainwright reaffirmed a “buy” rating and set a $34.00 price target on shares of Roivant Sciences in a research note on Thursday, May 21st. Sanford C. Bernstein initiated coverage on Roivant Sciences in a research note on Friday, March 20th. They issued an “outperform” rating and a $35.00 target price for the company. Leerink Partners set a $42.00 target price on Roivant Sciences in a research note on Thursday, May 21st. TD Cowen boosted their target price on Roivant Sciences from $38.00 to $41.00 and gave the company a “buy” rating in a research note on Thursday, May 21st. Finally, Piper Sandler reissued an “overweight” rating on shares of Roivant Sciences in a research note on Thursday, May 21st. Ten equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $33.59.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.